SGLT-2 inhibitors are classified as Class 1 agents in patients with heart failure with reduced ejection fraction (HFrEF) and Class 2a in patients with heart failure with preserved ejection fraction (HFpEF). The gene discussed is SLC5A2; the disease is heart failure.